Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. To aid in the development process, the Company incorporates its CNSProfile™, a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases

Type
Public
HQ
New York, US
Size (employees)
41 (est)+11%
Intra-Cellular Therapies is headquartered in New York, US

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has office in New York
New York, US

Intra-Cellular Therapies Metrics

Intra-Cellular Therapies Summary

Market capitalization

$641.4 m

Closing share price

$14.9
Intra-Cellular Therapies's current market capitalization is $641.4 m.

Intra-Cellular Therapies Financials

Intra-Cellular Therapies's revenue is $577.3 k in FY, 2014 which is a 531.9% increase from the previous period.
FY, 2014FY, 2015

Revenue

$577.3 k$91.4 k

Revenue growth, %

(79%)(84%)

R&D expense

$21.2 m$87.7 m

General and administrative expense

$10.3 m$18.2 m

Operating expense total

$31.6 m$105.9 m

EBIT

($31 m)($105.8 m)

EBIT margin, %

(5367.5%)(115815.9%)

Interest expense

$7.1 k

Interest income

$303.9 k$1 m

Income tax expense

$1.6 k$1.6 k

Pre tax profit

($30.7 m)($104.8 m)

Net Income

($30.7 m)($104.8 m)

Operating cash flow

$26.2 m($14.2 m)

Intra-Cellular Therapies Operating Metrics

Intra-Cellular Therapies had 80 Patent Families in FY, 2017
FY, 2017

Patent Families

80

Intra-Cellular Therapies Market Value History

Intra-Cellular Therapies Revenue Breakdown

We estimate that Intra-Cellular Therapies's current employees are approximately 22% female and 78% male.

Intra-Cellular Therapies News

Intra-Cellular Therapies Company Life

You may also be interested in